Asthma and Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report 2026

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has grown strongly in recent years. It will grow from $35.66 billion in 2025 to $39.07 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising smoking prevalence, urban air pollution, hospital-based respiratory care, inhaler technology adoption, growth in asthma diagnosis.

The asthma and chronic obstructive pulmonary disease (copd) drugs market size is expected to see strong growth in the next few years. It will grow to $55.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to biologic drug innovation, aging population, air quality deterioration, personalized respiratory medicine, homecare respiratory solutions. Major trends in the forecast period include increased use of combination inhaler therapies, growing adoption of long-acting bronchodilators, expansion of biologic therapies for severe asthma, shift toward home-based respiratory management, rising demand for generic inhalation drugs.

The rising prevalence of smoking is expected to drive the growth of the asthma and COPD drugs market in the coming years. Smoking, the habit of inhaling tobacco smoke, can lead to severe health issues, including lung cancer and heart disease. The increase in smoking is largely influenced by social factors such as peer pressure, cultural norms, and environmental encouragement to start and continue the habit. Asthma and chronic obstructive pulmonary disease (COPD) drugs help counteract the respiratory damage caused by smoking by reducing inflammation, relaxing airway muscles, and improving airflow, thereby alleviating symptoms and enhancing lung function. For example, in 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported that smoking rates among young people rose from 22.5% in 2022 to 40.1% in 2024. Therefore, the increasing prevalence of smoking is fueling growth in the asthma and COPD drugs market.

Key companies in the asthma and COPD drugs market are focusing on innovative combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers, to improve disease management, prevent severe asthma attacks, and enhance inflammation control. A SABA-ICS rescue inhaler combines a short-acting beta-agonist, which quickly relaxes airway muscles to relieve symptoms, with an inhaled corticosteroid, which reduces airway inflammation. This dual-action approach provides immediate symptom relief while addressing the underlying inflammatory condition. For instance, in January 2024, AstraZeneca, a UK-based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US, a fixed-dose SABA-ICS rescue inhaler delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA offers acute symptom relief while simultaneously reducing airway inflammation, lowering the risk of severe asthma exacerbations, and improving overall asthma control.

In February 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed amount. This acquisition aims to expand GSK’s asthma and respiratory biologics portfolio by incorporating Aiolos Bio’s investigational therapy, AIO‑001, a long-acting anti-TSLP monoclonal antibody for adult patients with severe asthma, including those with low T2 inflammation. Aiolos Bio Inc., based in the US, develops innovative treatments targeting unmet needs in respiratory conditions.

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the asthma and COPD drugs market by increasing the cost of APIs, inhaler components, and biologic ingredients used in bronchodilators, corticosteroids, and combination therapies. Inhalation-based drugs and biologics are most impacted, particularly in North America and Europe, which rely on global pharmaceutical and device supply chains. At the same time, tariffs are promoting domestic inhaler manufacturing and local API production, improving long-term market resilience.

The asthma and chronic obstructive pulmonary disease (copd) drugs market research report is one of a series of new reports that provides asthma and chronic obstructive pulmonary disease (copd) drugs market statistics, including asthma and chronic obstructive pulmonary disease (copd) drugs industry global market size, regional shares, competitors with a asthma and chronic obstructive pulmonary disease (copd) drugs market share, detailed asthma and chronic obstructive pulmonary disease (copd) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the asthma and chronic obstructive pulmonary disease (copd) drugs industry. This asthma and chronic obstructive pulmonary disease (copd) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Asthma and chronic obstructive pulmonary disease (COPD) drugs are medications used to treat and manage respiratory conditions that cause difficulty in breathing. They work by reducing inflammation, relaxing airway muscles, and improving airflow to the lungs, alleviating symptoms such as wheezing, coughing, and shortness of breath. These medications are commonly administered via inhalers or nebulizers to ensure effective delivery to the lungs.

The main drug classes for asthma and COPD include bronchodilators, corticosteroids, combination drugs, and leukotriene modifiers. Bronchodilators act by quickly relaxing airway muscles to widen breathing passages, providing rapid relief from asthma and COPD symptoms. These drugs can be administered through inhalation, oral, injection, nasal, and other routes. They are prescribed to adults, pediatric, and geriatric patients for conditions such as asthma, COPD, allergic rhinitis, and pulmonary hypertension. Distribution occurs through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.